These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24308780)

  • 1. Therapy response correlates with ALDH activity in ALDH low-positive childhood acute lymphoblastic leukemias.
    Ahlers J; Witte KE; Schwarze CP; Lang P; Handgretinger R; Ebinger M
    Pediatr Hematol Oncol; 2014 May; 31(4):303-10. PubMed ID: 24308780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia.
    Ebinger M; Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Lang P; Handgretinger R
    Leuk Res; 2010 Sep; 34(9):1139-42. PubMed ID: 20378168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
    Pawińska-Wasikowska K; Balwierz W
    Przegl Lek; 2010; 67(6):361-5. PubMed ID: 21344762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
    Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
    Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
    Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
    Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
    Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.
    Dworzak MN; Gaipa G; Schumich A; Maglia O; Ratei R; Veltroni M; Husak Z; Basso G; Karawajew L; Gadner H; Biondi A
    Cytometry B Clin Cytom; 2010 May; 78(3):147-53. PubMed ID: 20201055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.
    Xu XJ; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2012 Aug; 36(8):1022-7. PubMed ID: 22483330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
    Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 9-O-acetylated sialic acids differentiating normal haematopoietic precursors from leukemic stem cells with high aldehyde dehydrogenase activity in children with acute lymphoblastic leukaemia.
    Chowdhury S; Chandra S; Mandal C
    Glycoconj J; 2014 Oct; 31(6-7):523-35. PubMed ID: 25283637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
    Lönnerholm G; Thörn I; Sundström C; Frost BM; Abrahamsson J; Behrendtz M; Heldrup J; Jacobsson S; Li A; Olofsson T; Porwit A; Söderhäll S; Larsson R; Forestier E
    Leuk Res; 2009 Jan; 33(1):46-53. PubMed ID: 18639340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
    Schuurhuis GJ; Meel MH; Wouters F; Min LA; Terwijn M; de Jonge NA; Kelder A; Snel AN; Zweegman S; Ossenkoppele GJ; Smit L
    PLoS One; 2013; 8(11):e78897. PubMed ID: 24244383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential.
    Cheung AM; Wan TS; Leung JC; Chan LY; Huang H; Kwong YL; Liang R; Leung AY
    Leukemia; 2007 Jul; 21(7):1423-30. PubMed ID: 17476279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
    Yamaji K; Okamoto T; Yokota S; Watanabe A; Horikoshi Y; Asami K; Kikuta A; Hyakuna N; Saikawa Y; Ueyama J; Watanabe T; Okada M; Taga T; Kanegane H; Kogawa K; Chin M; Iwai A; Matsushita T; Shimomura Y; Hori T; Tsurusawa M;
    Pediatr Blood Cancer; 2010 Dec; 55(7):1287-95. PubMed ID: 20535816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
    Paganin M; Fabbri G; Conter V; Barisone E; Polato K; Cazzaniga G; Giraldi E; Fagioli F; Aricò M; Valsecchi MG; Basso G
    J Clin Oncol; 2014 Nov; 32(31):3553-8. PubMed ID: 25287825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.